APR 2 2026
Kite — Tecartus (brexucabtagene autoleucel)
for relapsed or refractory mantle cell lymphoma
FDA granted full approval to Kite's CAR T-cell therapy Tecartus for adult patients with relapsed or refractory mantle cell lymphoma.
About
Mantle cell lymphoma is a type of non-Hodgkin's lymphoma that develops in the lymph nodes. Tecartus is a treatment made from a patient's own immune cells, which are genetically engineered to find and attack lymphoma cells. This targeted immune attack may provide a treatment option for patients whose cancer has returned or stopped responding to other therapies.
Pivotal trial
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Tecartus
- Maria Babak: FDA Approves Tecartus in Relapsed or Refractory Mantle Cell Lymphoma - Oncodaily
- FDA Fully Approves Brexucabtagene Autoleucel (Tecartus) for Relapsed or Refractory Mantle Cell Lymphoma - Oncology News Central
- FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL - The ASCO Post
- FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma - Cure Today
- Tecartus Gains Full FDA Approval for R/R Mantle Cell Lymphoma - MPR - Medical Professionals Reference